Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results of the phase II STORM study.
Heavily-refractory myeloma patients who have exhausted available treatment agents were able to achieve a response with the investigational agent selinexor. Dr. Vogl shares results of the phase II STORM study.
Connect with us:
CURRENT ISSUE
June 2025
